Vitae Pharmaceuticals Company Profile (NASDAQ:VTAE)

Analyst Ratings

Consensus Ratings for Vitae Pharmaceuticals (NASDAQ:VTAE) (?)
Ratings Breakdown: 6 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $19.00 (76.58% upside)

Analysts' Ratings History for Vitae Pharmaceuticals (NASDAQ:VTAE)
Show:
DateFirmActionRatingPrice TargetActions
6/10/2016Wells Fargo & Co.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/25/2016WedbushReiterated RatingOutperform$23.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
4/11/2016BMO Capital MarketsInitiated CoverageOutperform$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/20/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/17/2016JMP SecuritiesUpgradeMarket Perform -> OutperformView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/17/2016Stifel NicolausUpgradeHold -> Buy$15.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/24/2014 forward)

Earnings

Earnings History for Vitae Pharmaceuticals (NASDAQ:VTAE)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/2/2016        
5/10/2016Q1($0.51)($0.44)$0.05 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/3/2016Q415($0.62)($0.52)$0.14 million$0.09 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q315($0.48)($0.60)$0.18 million$0.18 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/4/2015Q215($0.45)($0.45)$0.09 million$0.16 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/13/2015Q115($0.33)($0.47)$0.08 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/31/2015Q414($0.45)($0.40)$0.19 million$0.16 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/12/2014Q3($0.13)($1.03)$6.39 million$6.18 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Vitae Pharmaceuticals (NASDAQ:VTAE)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.39)($0.39)($0.39)
Q2 20161($0.35)($0.35)($0.35)
Q3 20161($0.33)($0.33)($0.33)
Q4 20161($0.33)($0.33)($0.33)
Q1 20171($0.33)($0.33)($0.33)
Q2 20171($0.33)($0.33)($0.33)
Q3 20171($0.30)($0.30)($0.30)
Q4 20171($0.28)($0.28)($0.28)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Vitae Pharmaceuticals (NASDAQ:VTAE)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Vitae Pharmaceuticals (NASDAQ:VTAE)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/21/2016Donald J Hayden JrDirectorSell16,130$7.42$119,684.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/29/2015Donald J. Hayden, Jr.DirectorSell16,130$18.00$290,340.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/23/2015Jeffrey S. HatfieldCEOSell22,524$17.00$382,908.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/21/2015Donald J. Hayden, Jr.DirectorSell16,130$17.00$274,210.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2014Peter BarrettDirectorBuy37,500$8.00$300,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2014Venrock Management Iii LlcMajor ShareholderBuy772,333$8.00$6,178,664.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Vitae Pharmaceuticals (NASDAQ:VTAE)
DateHeadline
07/23/16 10:30 AMVitae Pharmaceuticals, Inc. (NASDAQ:VTAE): Sell-Side Ratings and Company Earnings Glance - Engelwood Daily
07/23/16 10:30 AMVitae Pharmaceuticals Incorporated (NASDAQ:VTAE) Shorted Shares Increased By 1.36% - Consumer Eagle
07/21/16 07:33 PMStock Moving Lower for the Month; Investor Update on Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Engelwood Daily
07/19/16 08:07 AMVitae Pharmaceuticals Incorporated (NASDAQ:VTAE) Sellers Covered 8.81% of Their Shorts - Consumer Eagle
07/18/16 06:11 AMAre Analysts Bullish Vitae Pharmaceuticals Inc (NASDAQ:VTAE) After Last Week? - Consumer Eagle
07/17/16 06:16 AMShares Moving Down on the Week: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Engelwood Daily
07/16/16 10:21 AMAnalyst Target and Average Rating Watch: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Press Telegraph
07/16/16 10:21 AMShares Experiencing a Downtrend: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - TGP
07/16/16 10:21 AMVitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Earnings Concentration and Analyst Target Watch - Engelwood Daily
07/14/16 07:26 PMOption Market: Vitae Pharmaceuticals Inc Risk Hits An Elevated Level - CML News
07/13/16 10:01 AMVitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Wall Street Analyst Recommendation Outlook - Telanagana Press
07/13/16 10:01 AM2016 Q1 Sentiment Vitae Pharmaceuticals (NASDAQ:VTAE) - Consumer Eagle
07/12/16 07:25 PMVitae Pharmaceuticals Incorporated (NASDAQ:VTAE) Shorts Decreased by 8.81% After Short Covering - Press Telegraph
07/11/16 05:46 AMStock on the Rise for the Quarter: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Engelwood Daily
07/11/16 05:46 AMStock Rating Watch and Earnings Insight for Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Press Telegraph
07/10/16 06:01 AMWere Analysts Bullish Vitae Pharmaceuticals Inc (NASDAQ:VTAE) This Week? - Engelwood Daily
07/08/16 09:59 AMCan Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Improve on the Earnings Front? - Engelwood Daily
07/08/16 09:59 AMCompany Stock Focus for Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE): Which Way Will Shares Head? - Press Telegraph
07/06/16 05:46 AMVitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Stock Update: Check on Ratings and Target Price - Telanagana Press
07/03/16 05:49 AMHow Many Vitae Pharmaceuticals Inc (NASDAQ:VTAE)'s Analysts Are Bearish? - Press Telegraph
07/02/16 09:44 AMDafna Capital Management LLC Increased Vitae Pharmaceuticals INC (NASDAQ:VTAE) by $3.56 Million as Shares ... - Engelwood Daily
06/30/16 03:12 PMVITAE PHARMACEUTICALS, INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and E -
06/30/16 09:52 AMVitae Pharmaceuticals, Inc. (VTAE) Updated Price Targets - FTSE News
06/29/16 09:52 AMCheck on Share Volatility: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Engelwood Daily
06/29/16 09:52 AMVitae Pharmaceuticals Incorporated (NASDAQ:VTAE) Short Interest Decreased By 8.81% - Press Telegraph
06/29/16 09:52 AMVitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Company Rating and Target Watch - Telanagana Press
06/27/16 05:43 AMShare Update and Earnings Review for Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Press Telegraph
06/26/16 05:53 AMHow Many Vitae Pharmaceuticals Inc (NASDAQ:VTAE)'s Analysts Are Bullish? - Press Telegraph
06/25/16 06:28 PMShare Volatility Check for: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Press Telegraph
06/24/16 09:48 AMCovering the Bases on Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE): Where is the Stock Going? - Press Telegraph
06/24/16 09:48 AMVitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Earnings Glance and Target Price Review - Engelwood Daily
06/24/16 09:48 AMDafna Capital Management LLC Increased Vitae Pharmaceuticals INC (NASDAQ:VTAE) by $3.56 Million as Shares ... - Press Telegraph
06/24/16 09:48 AMVitae Pharmaceuticals, Inc. (VTAE) Current Analyst Ratings - Fiscal Standard
06/21/16 05:55 AMThis Weeks Broker Views For Vitae Pharmaceuticals, Inc. (VTAE) - Fiscal Standard
06/17/16 06:55 PMVitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Fell -2.14%: Cavium, Inc. (NASDAQ:CAVM), QLogic Corp. (NASDAQ ... - KC Register
06/17/16 06:55 PMVitae Pharmaceuticals (VTAE) Is Weak On High Volume Today - TheStreet.com
06/14/16 03:29 PMVitae Pharmaceuticals to Present at JMP Securities Life Sciences Conference - [at noodls] - FORT WASHINGTON, Pa., June 14, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Richard Gregg, M.D., Chief Scientific Officer, ...
06/06/16 03:38 PMVitae Pharmaceuticals Announces Appointment of Carole Sable, M.D., as Chief Medical Officer - [at noodls] - FORT WASHINGTON, Pa., June 06, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE), a clinical-stage biotechnology company, today announced that Carole Sable, M.D., has been named Chief ...
06/03/16 10:17 AMShare Rating Focus on Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - HNN
06/02/16 07:46 PMStock in Overbought Territory: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - HNN - Stock in Overbought Territory: Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE)HNNShares of Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) have entered overbought territory as the 14-day RSI reading touched 80.45 after yesterday's close. Investors should be cautious of taking positions as this might indicate the stock is due to reverse ...
06/02/16 10:31 AMTarget Price and Stock Performance Rundown for Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - HNN - Target Price and Stock Performance Rundown for Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE)HNNDuring the latest trading session, Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) shares traded +6.28%. Monitoring the stock price relative to moving averages may offer enhanced perspective on stock performance. After a recent check, shares have been seen ...and more »
05/30/16 10:30 PMVitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Daily Sentiment Score Of 0.435 - Stocks Daily - Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Daily Sentiment Score Of 0.435Stocks DailyVitae Pharmaceuticals, Inc. (NASDAQ:VTAE) has a daily sentiment score of 0.435. This score is given by Alpha One, which uses its self-designed algorithm to identify market sentiment on the stock after studying the published content on the web. The ...and more »
05/30/16 10:30 PMNext Weeks Broker Price Targets For Vitae Pharmaceuticals, Inc. (VTAE) - Share Trading News - Next Weeks Broker Price Targets For Vitae Pharmaceuticals, Inc. (VTAE)Share Trading News04/11/2016 – BMO Capital Markets began new coverage on Vitae Pharmaceuticals, Inc. giving the company a “outperform” rating. They now have a USD 15 price target on the stock. 03/17/2016 – Vitae Pharmaceuticals, Inc. was upgraded to “mkt outperform” ...Vitae Pharmaceuticals Incorporated (NASDAQ:VTAE) Shorted Shares Increased By 7.08%HNNall 4 news articles »
05/28/16 09:40 AMDafna Capital Management LLC Increased Vitae Pharmaceuticals INC (NASDAQ:VTAE) by $3.56 Million as Shares ... - CCH Daily News - Dafna Capital Management LLC Increased Vitae Pharmaceuticals INC (NASDAQ:VTAE) by $3.56 Million as Shares ...CCH Daily NewsNathan Fischel increased its stake in Vitae Pharmaceuticals Inc (NASDAQ:VTAE) by 307.49% based on its latest 2016Q1 regulatory filing with the SEC. Dafna Capital Management Llc bought 594,149 shares as the company's stock declined 61.65% while ...
05/27/16 10:45 AMStock Rating Review for Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Wall Street Hints and News - Stock Rating Review for Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE)Wall Street Hints and NewsInvestors may choose to follow the views of professional Wall Street analysts that regularly track the company. Covering equity analysts presently have a consensus stock rating of 1 on shares of Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE). Covering ...Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) Tracking Stock Rating and Target ProjectionsThe PostHold Calls Count For Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) At 0Vanguard Tribuneall 653 news articles »
05/27/16 10:45 AMLatest Analyst Ratings For Vitae Pharmaceuticals, Inc. (VTAE) - Share Trading News - Latest Analyst Ratings For Vitae Pharmaceuticals, Inc. (VTAE)Share Trading News04/11/2016 – BMO Capital Markets began new coverage on Vitae Pharmaceuticals, Inc. giving the company a “outperform” rating. They now have a USD 15 price target on the stock. 03/17/2016 – Vitae Pharmaceuticals, Inc. was upgraded to “mkt outperform” ...and more »
05/26/16 03:32 PMVITAE PHARMACEUTICALS, INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/26/16 05:22 AMTarget Check and Stock Performance Recap Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE) - Wall Street Hints and News - Target Check and Stock Performance Recap Vitae Pharmaceuticals, Inc. (NASDAQ:VTAE)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Vitae Pharmaceuticals, Inc.and more »
05/10/16 03:08 PMVitae Pharmaceuticals Reports First Quarter 2016 Operating and Financial Results - [at noodls] - Proof-of-concept data for VTP-38543 expected in the second half of 2016 Conference call scheduled for 4:30 p.m. EDT today FORT WASHINGTON, Pa., May 10, 2016 (GLOBE NEWSWIRE) -- Vitae Pharmaceuticals, Inc. ...
05/10/16 06:07 AMQ1 2016 Vitae Pharmaceuticals Inc Earnings Release - After Market Close -

Social

About Vitae Pharmaceuticals

Vitae Pharmaceuticals logoVitae Pharmaceuticals, Inc. is a biotechnology company. The Company is focused on discovering and developing small molecule drugs for diseases. It is engaged in developing a portfolio of product candidates through Contour, its structure-based drug discovery platform. The Company's product candidates include VTP- 43742 for the treatment of psoriasis, as well as multiple other autoimmune disorders. The Company completed approximately two Phase I studies with VTP-43742. Its VTP-38543, a second product candidate is in a Phase IIa proof-of-concept clinical trial for the treatment of atopic dermatitis. Its VTP-36951 is for the treatment and prevention of Alzheimer's disease, or Alzheimer's. VTP-43742, the Company's wholly owned clinical candidate in an on-going Phase IIa proof-of-concept trial in psoriasis, is an orally active small molecule inhibitor of Retinoic acid-receptor (RAR)-Related Orphan Receptor gamma-t (RORgt) activity for the treatment of various autoimmune disorders.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Exchange: NASDAQ
  • Symbol: VTAE
  • CUSIP:
Key Metrics:
  • Previous Close: $10.76
  • 50 Day Moving Average: $10.40
  • 200 Day Moving Average: $8.93
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $310.33M
  • Beta: 1.12
  • Current Year EPS Consensus Estimate: $-1.71 EPS
  • Next Year EPS Consensus Estimate: $-1.9 EPS
Additional Links:
Vitae Pharmaceuticals (NASDAQ:VTAE) Chart for Sunday, July, 24, 2016